SHARP is mislocalized in myotonic dystrophy [228], while, in acute myeloid leukemia (AML), it has been proposed to have an altered function as consequence of its interaction with the oncofusion protein AML1/ETO deregulating the Notch signaling pathway [173,174]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.